Outlook
- Tyra expects initial Phase 2 data from SURF302 in September 2026.
- Company expects initial Phase 2 data from BEACH301 safety sentinel cohort at the end of Q1 2027.
- Initial results from SURF303 Phase 2 study expected in 2027.
Overview
- U.S. biotech firm reported Q2 net loss widened year over year as R&D expenses increased.
- Company ended Q2 with $353.9 million in cash, cash equivalents and marketable securities.
- Amended ATM agreement allows up to $250 million in additional at-the-market share sales.
Result drivers
- R&D spending — Company said higher R&D expenses were mainly due to development activities for oral dabogratinib in ongoing SURF303, SURF302 and BEACH301 clinical trials.
- Headcount growth — Company said increased personnel expenses contributed to higher R&D and G&A costs.
Key details and analyst coverage
TYRA•
